.Pharmacolibrary.Drugs.ATC.N.N06DA03

Information

Rivastigmine is a reversible cholinesterase inhibitor approved for the symptomatic treatment of mild to moderate dementia related to Alzheimer’s and Parkinson’s diseases. It enhances cholinergic function by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by cholinesterase.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers following single oral dose administration.

References

1. Lalli, S, & Albanese, A (2008). Rivastigmine in Parkinson's disease dementia. Expert review of neurotherapeutics 8(8) 1181–1188. DOI:10.1586/14737175.8.8.1181 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18671661

2. Hossain, M, et al., & Cutler, NR (2002). Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clinical pharmacokinetics 41(3) 225–234. DOI:10.2165/00003088-200241030-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11929322

3. Mercier, F, et al., & Appel-Dingemanse, S (2007). Rivastigmine exposure provided by a transdermal patch versus capsules. Current medical research and opinion 23(12) 3199–3204. DOI:10.1185/030079908X253438 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18001519

Revisions

• 06/2025 initial generated model